Holguin with Good Results in Clinical Trials
- Written by Lourdes Pichs Rodríguez
- Published in Health
- Hits: 2150
Photos: ACNHolguin is among the Cuban provinces with the largest number of coordinated and not coordinated protocols assumed by the National Center for Clinical Trials (CENCEC), with a stable and functional structure, as well as for its informative discipline. Currently there are 95 protocols assumed by the province, of which 70 are closed, although some keep patients in treatment, 22 in execution while three protocols on Prostate, Spinocerebellar Ataxia and lymphoma will start in 2018, said Dr. Zaimar Rodríguez Feria, head of the Provincial Clinical Trial Group.
According to the specialist, the most influential in prolonging the life of patients are hR3 or Nimotuzumab for various cancer localizations, Epidermal Growth Factor (EGF) gradually extended to Primary Health Care (PHC) of the territory and the Incarbacel IV for skin cancer.
The three provincial hospitals are included in the studies, although the "Vladimir Ilich Lenin" is more important as the Oncology Territorial Center is located in this institution and the bulk of the studies are related to cancer.Also some of the trials are already incorporated or in the implementation phase in the primary health care of several municipalities, among them Holguín, Gibara, Moa, Banes, Calixto García, Urbano Noris, Cueto, Rafael Freyre, Báguano and Mayarí.
Protocols mainly work on therapeutic vaccines against different types of cancer, bronchial asthma and hereditary ataxia.In 1993 Holguín joined these investigations with three clinical trials, the use of recombinant streptokinase for acute myocardial infarction and interferon alfa in respiratory papillomatosis in children and adults and progressively has been introducing studies in clinical sites of the PHC and secondary health care.
